NMRK2 Serves as a Diagnostic Biomarker for Renal Cell Carcinoma: Preclinical Findings

Synopsis

Xp11.2 translocation renal cell carcinoma (tRCC) is a rare and aggressive form of kidney cancer that currently lacks reliable diagnostic tools and effective treatments. This study identified NMRK2, an enzyme involved in NAD+ metabolism, as a specific biomarker for distinguishing Xp11.2 tRCC from other kidney cancer types, such as clear cell carcinoma (KIRC) and papillary carcinoma (KIRP). The researchers found that TFE3 fusion proteins, which are characteristic of this cancer subtype, activate NMRK2 by binding to its gene promoter, leading to its overexpression. Using RNA- and protein-based tests, they confirmed that measuring NMRK2 levels can accurately diagnose Xp11.2 tRCC, performing as well as current genetic testing methods. Functionally, NMRK2 promotes tumor progression by increasing the NAD+/NADH ratio, supporting cancer cell metabolism. When NMRK2 was silenced, tumor growth slowed—but this effect was reversed by supplementation with nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), both NAD+ precursors. These findings reveal NMRK2 as both a diagnostic marker and a potential therapeutic target, paving the way for metabolism-based treatments in this aggressive kidney cancer.

Journal

The Journal of Pathology